SCHEMBL5990792

SCHEMBL5990792

Oc1c(Br)cc(C(c2ccccc2)(c2ccccc2)c2ccccc2)cc1Br

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.54
CRHR2 Q13324 1/20 0.54
TSHR P16473 3/20 0.50
HIF1A Q16665 3/20 0.50
ALOX15 P16050 2/20 0.50
ALOX12 P18054 2/20 0.50
CYP3A4 P08684 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
HSD17B10 Q99714 2/20 0.50
ALDH1A1 P00352 2/20 0.50
HPGD P15428 1/20 0.50
CASP1 P29466 1/20 0.50
RECQL P46063 1/20 0.50
CYP2C9 P11712 2/20 0.41
TTR P02766 2/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
MAPT P10636 2/20 0.40
MAPK1 P28482 1/20 0.40
GFER P55789 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8673233 1.00 CRHBP (0.54) CRHBPCRHR2TSHRHIF1AALOX15
SCHEMBL8676214 0.79 ALOX15 (0.50) CRHBPCRHR2TSHRHIF1AALOX15
SCHEMBL27546691 0.79 ALOX15 (0.50) CRHBPCRHR2TSHRHIF1AALOX15
SCHEMBL8623383 0.79 CYP3A4 (0.76) CRHBPCRHR2TSHRHIF1AALOX15
SCHEMBL9682952 0.79 ALDH1A1 (0.57) CRHBPCRHR2TSHRHIF1AALOX15
SCHEMBL24174896 0.78 GAA (0.42) TSHRHIF1ATDP1ALDH1A1MAPT
SCHEMBL26624383 0.78 TSHR (0.37) CRHBPCRHR2TSHRTDP1ALDH1A1
SCHEMBL23861355 0.77 ESR1 (0.39) HIF1AALOX15CYP3A4TDP1HSD17B10
SCHEMBL4601584 0.76 PTGS1 (0.50) ALOX15CYP3A4ALDH1A1CYP2C9TTR
SCHEMBL25708111 0.75 ALDH1A1 (0.41) TSHRTDP1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7008636-B2 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia WYETH (US) 2006-03-07 US disclosed
US-20040214869-A1 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia WYETH 2004-10-28 US disclosed
US-6765021-B2 ANTIDIABETIC AGENTS WYETH 2004-07-20 US disclosed
US-20030083341-A1 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia WYETH 2003-05-01 US disclosed
US-6451827-B2 MODULATING BLOOD GLUCOSE CONCENTRATION WYETH 2002-09-17 US disclosed
US-20010018525-A1 2, 3, 5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia WYETH 2001-08-30 US disclosed
US-6214877-B1 ANTIDIABETIC AGENTS; MODULATOR OF GLUCOSE CONCENTRATION WYETH 2001-04-10 US disclosed
EP-1077929-A1 2,3,5-SUBSTITUTED BIPHENYLS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 EP disclosed
WO-1999061410-A1 2,3,5-SUBSTITUTED BIPHENYLS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083341-A1 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia INSR, GPR119, IRS1 CRHBP 1285/4885CRHR2 33/4885TSHR 88/4885
US-20010018525-A1 2, 3, 5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia INSR, GPR119, IRS1 CRHBP 1287/4885CRHR2 33/4885TSHR 88/4885
US-20040214869-A1 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia INSR, GPR119, IRS1 CRHBP 1285/4885CRHR2 33/4885TSHR 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.